Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system

A. Wayne Meikle, Stefan Arver, Adrian S. Dobs, Jan Adolfsson, Steven W. Sanders, Richard G. Middleton, Robert A. Stephenson, Donald Hoover, Lakshiminaryan Rajaram, Norman A. Mazer

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Objectives. This study examined the effects of testosterone replacement using a nonscrotal testosterone transdermal (TTD) system on prostate size and prostate-specific antigen (PSA) levels in hypogonadal men. Methods. As part of an open-label, multicenter study, prostate volume as measured by transrectal ultrasound and PSA were assessed in 29 hypogonadal men during treatment with intramuscular testosterone enanthate (+TE), followed by 8 weeks of androgen withdrawal (-T), and then during 1 year of therapy with Androderm Testosterone Transdermal System, a nonscrotal permeation-enhanced TTD system (+TTD). Results. Mean prostate volume decreased significantly from the +TE period (17 g) compared with the T period (14 g) (P <0.001). Prostate volume increased significantly from the -T period compared with the +TTD period (18 g) (P <0.001). Maximum prostate size, comparable to that measured during +TE (P = 0.125), was reached by month 3 of +TTD therapy; prostate volume did not increase further during the remaining 9 months of +TTD therapy. Prostate volume correlated with age (P <0.01) during all three periods of observation (+TE: r = 0.69; T: r = 0.64; and +TTD: r = 0.55). No patient developed symptomatic benign prostatic hyperplasia during the treatment period. PSA levels decreased during androgen withdrawal compared with levels measured during +TE treatment (P <0.001) and rose with resumption of androgen therapy with TTD (P <0.006). However, PSA levels during +TTD replacement remained significantly lower (P <0.001) than during +TE replacement. Conclusions. Physiologic testosterone replacement in hypogonadal men was achieved using the TTD system. Prostate size during therapy with TTD was comparable to that reported for normal men. In these men treated with TTD, PSA levels were also within the normal range.

Original languageEnglish (US)
Pages (from-to)191-196
Number of pages6
JournalUrology
Volume49
Issue number2
DOIs
StatePublished - Feb 1 1997
Externally publishedYes

Fingerprint

Testosterone
Prostate
Prostate-Specific Antigen
Androgens
Therapeutics
Prostatic Hyperplasia
Multicenter Studies
Reference Values
Observation

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Meikle, A. W., Arver, S., Dobs, A. S., Adolfsson, J., Sanders, S. W., Middleton, R. G., ... Mazer, N. A. (1997). Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system. Urology, 49(2), 191-196. https://doi.org/10.1016/S0090-4295(96)00445-1
Meikle, A. Wayne ; Arver, Stefan ; Dobs, Adrian S. ; Adolfsson, Jan ; Sanders, Steven W. ; Middleton, Richard G. ; Stephenson, Robert A. ; Hoover, Donald ; Rajaram, Lakshiminaryan ; Mazer, Norman A. / Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system. In: Urology. 1997 ; Vol. 49, No. 2. pp. 191-196.
@article{470bd07b428446d78ef3ba96ea1b7508,
title = "Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system",
abstract = "Objectives. This study examined the effects of testosterone replacement using a nonscrotal testosterone transdermal (TTD) system on prostate size and prostate-specific antigen (PSA) levels in hypogonadal men. Methods. As part of an open-label, multicenter study, prostate volume as measured by transrectal ultrasound and PSA were assessed in 29 hypogonadal men during treatment with intramuscular testosterone enanthate (+TE), followed by 8 weeks of androgen withdrawal (-T), and then during 1 year of therapy with Androderm Testosterone Transdermal System, a nonscrotal permeation-enhanced TTD system (+TTD). Results. Mean prostate volume decreased significantly from the +TE period (17 g) compared with the T period (14 g) (P <0.001). Prostate volume increased significantly from the -T period compared with the +TTD period (18 g) (P <0.001). Maximum prostate size, comparable to that measured during +TE (P = 0.125), was reached by month 3 of +TTD therapy; prostate volume did not increase further during the remaining 9 months of +TTD therapy. Prostate volume correlated with age (P <0.01) during all three periods of observation (+TE: r = 0.69; T: r = 0.64; and +TTD: r = 0.55). No patient developed symptomatic benign prostatic hyperplasia during the treatment period. PSA levels decreased during androgen withdrawal compared with levels measured during +TE treatment (P <0.001) and rose with resumption of androgen therapy with TTD (P <0.006). However, PSA levels during +TTD replacement remained significantly lower (P <0.001) than during +TE replacement. Conclusions. Physiologic testosterone replacement in hypogonadal men was achieved using the TTD system. Prostate size during therapy with TTD was comparable to that reported for normal men. In these men treated with TTD, PSA levels were also within the normal range.",
author = "Meikle, {A. Wayne} and Stefan Arver and Dobs, {Adrian S.} and Jan Adolfsson and Sanders, {Steven W.} and Middleton, {Richard G.} and Stephenson, {Robert A.} and Donald Hoover and Lakshiminaryan Rajaram and Mazer, {Norman A.}",
year = "1997",
month = "2",
day = "1",
doi = "10.1016/S0090-4295(96)00445-1",
language = "English (US)",
volume = "49",
pages = "191--196",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

Meikle, AW, Arver, S, Dobs, AS, Adolfsson, J, Sanders, SW, Middleton, RG, Stephenson, RA, Hoover, D, Rajaram, L & Mazer, NA 1997, 'Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system', Urology, vol. 49, no. 2, pp. 191-196. https://doi.org/10.1016/S0090-4295(96)00445-1

Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system. / Meikle, A. Wayne; Arver, Stefan; Dobs, Adrian S.; Adolfsson, Jan; Sanders, Steven W.; Middleton, Richard G.; Stephenson, Robert A.; Hoover, Donald; Rajaram, Lakshiminaryan; Mazer, Norman A.

In: Urology, Vol. 49, No. 2, 01.02.1997, p. 191-196.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system

AU - Meikle, A. Wayne

AU - Arver, Stefan

AU - Dobs, Adrian S.

AU - Adolfsson, Jan

AU - Sanders, Steven W.

AU - Middleton, Richard G.

AU - Stephenson, Robert A.

AU - Hoover, Donald

AU - Rajaram, Lakshiminaryan

AU - Mazer, Norman A.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - Objectives. This study examined the effects of testosterone replacement using a nonscrotal testosterone transdermal (TTD) system on prostate size and prostate-specific antigen (PSA) levels in hypogonadal men. Methods. As part of an open-label, multicenter study, prostate volume as measured by transrectal ultrasound and PSA were assessed in 29 hypogonadal men during treatment with intramuscular testosterone enanthate (+TE), followed by 8 weeks of androgen withdrawal (-T), and then during 1 year of therapy with Androderm Testosterone Transdermal System, a nonscrotal permeation-enhanced TTD system (+TTD). Results. Mean prostate volume decreased significantly from the +TE period (17 g) compared with the T period (14 g) (P <0.001). Prostate volume increased significantly from the -T period compared with the +TTD period (18 g) (P <0.001). Maximum prostate size, comparable to that measured during +TE (P = 0.125), was reached by month 3 of +TTD therapy; prostate volume did not increase further during the remaining 9 months of +TTD therapy. Prostate volume correlated with age (P <0.01) during all three periods of observation (+TE: r = 0.69; T: r = 0.64; and +TTD: r = 0.55). No patient developed symptomatic benign prostatic hyperplasia during the treatment period. PSA levels decreased during androgen withdrawal compared with levels measured during +TE treatment (P <0.001) and rose with resumption of androgen therapy with TTD (P <0.006). However, PSA levels during +TTD replacement remained significantly lower (P <0.001) than during +TE replacement. Conclusions. Physiologic testosterone replacement in hypogonadal men was achieved using the TTD system. Prostate size during therapy with TTD was comparable to that reported for normal men. In these men treated with TTD, PSA levels were also within the normal range.

AB - Objectives. This study examined the effects of testosterone replacement using a nonscrotal testosterone transdermal (TTD) system on prostate size and prostate-specific antigen (PSA) levels in hypogonadal men. Methods. As part of an open-label, multicenter study, prostate volume as measured by transrectal ultrasound and PSA were assessed in 29 hypogonadal men during treatment with intramuscular testosterone enanthate (+TE), followed by 8 weeks of androgen withdrawal (-T), and then during 1 year of therapy with Androderm Testosterone Transdermal System, a nonscrotal permeation-enhanced TTD system (+TTD). Results. Mean prostate volume decreased significantly from the +TE period (17 g) compared with the T period (14 g) (P <0.001). Prostate volume increased significantly from the -T period compared with the +TTD period (18 g) (P <0.001). Maximum prostate size, comparable to that measured during +TE (P = 0.125), was reached by month 3 of +TTD therapy; prostate volume did not increase further during the remaining 9 months of +TTD therapy. Prostate volume correlated with age (P <0.01) during all three periods of observation (+TE: r = 0.69; T: r = 0.64; and +TTD: r = 0.55). No patient developed symptomatic benign prostatic hyperplasia during the treatment period. PSA levels decreased during androgen withdrawal compared with levels measured during +TE treatment (P <0.001) and rose with resumption of androgen therapy with TTD (P <0.006). However, PSA levels during +TTD replacement remained significantly lower (P <0.001) than during +TE replacement. Conclusions. Physiologic testosterone replacement in hypogonadal men was achieved using the TTD system. Prostate size during therapy with TTD was comparable to that reported for normal men. In these men treated with TTD, PSA levels were also within the normal range.

UR - http://www.scopus.com/inward/record.url?scp=0031019638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031019638&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00445-1

DO - 10.1016/S0090-4295(96)00445-1

M3 - Article

VL - 49

SP - 191

EP - 196

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -